During the past decade, Gastroenterologische Gemeinschaftspraxis Minden conducted 19 clinical trials. In the 10-year time frame, 19 clinical trials started and 14 clinical trials were completed, i.e. on average, 73.7% percent of trials that started reached the finish line to date. In the past 5 years, 5 clinical trials started and 5 clinical trials were completed. i.e. 100% of trials that started reached the finish line.

Out of the total clinical trials conducted in "Gastroenterologische Gemeinschaftspraxis Minden" #1 sponsor was "Pfizer" with 8 trials, followed by "Galapagos NV" with 5 trials sponsored, "Ced Service GmbH" with 3 trials sponsored, "Celgene" with 2 trials sponsored and "Ferring Pharmaceuticals" with 2 trials sponsored. Other sponsors include 5 different institutions and companies that sponsored additional 12 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "Gastroenterologische Gemeinschaftspraxis Minden" #1 collaborator was "Gilead Sciences" with 3 trials as a collaborator, "Dr. Falk Pharma GmbH" with 1 trials as a collaborator, "Galapagos NV" with 1 trials as a collaborator, "Hospira, now a wholly owned subsidiary of Pfizer" with 1 trials as a collaborator and "Pfizer" with 1 trials as a collaborator. Other collaborators include -5 different institutions and companies that were collaborators in the rest 5 trials.

According to Clinical.Site data, the most researched conditions in "Gastroenterologische Gemeinschaftspraxis Minden" are "Crohn's Disease" (12 trials), "Ulcerative Colitis" (9 trials), "Colitis, Ulcerative" (4 trials), "Crohn Disease" (4 trials) and "Inflammatory Bowel Diseases" (2 trials). Many other conditions were trialed in "Gastroenterologische Gemeinschaftspraxis Minden" in a lesser frequency.

Most popular intervention types in "Gastroenterologische Gemeinschaftspraxis Minden" are "Drug" (25 trials), "Biological" (6 trials) and "Other" (2 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (14 trials), "Filgotinib" (4 trials), "CP-690,550" (3 trials), "GED-0301" (2 trials) and "Golimumab" (2 trials). Other intervention names were less common.

The vast majority of trials in "Gastroenterologische Gemeinschaftspraxis Minden" are 30 trials for "All" genders.

Currently, there are NaN active trials in "Gastroenterologische Gemeinschaftspraxis Minden". undefined are not yet recruiting, 3 are recruiting, 1 are Active, not recruiting, and 1 are Enrolling by invitation. In total, there were 19 completed trials in Gastroenterologische Gemeinschaftspraxis Minden, undefined suspended trials, and 4 terminated clinical trials to date.

Out of the total trials that were conducted in Gastroenterologische Gemeinschaftspraxis Minden, 0 "Phase 1" clinical trials were conducted, 15 "Phase 2" clinical trials and 10 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 0 trials, and there were also 0 trials that are defined as “Not Applicable".